Health technology assessment and haemophilia. - Wikidata - wikimedia - TriplyDB

Health technology assessment and haemophilia.

Health technology assessment and haemophilia.

http://www.wikidata.org/entity/Q37984093

about

Estimates of utility weights in hemophilia: implications for cost-utility analysis of clotting factor prophylaxis Using value-of-information methods when the disease is rare and the treatment is expensive--the example of hemophilia A.Principles for consistent value assessment and sustainable funding of orphan drugs in Europe.Costs and utilization of treatment in patients with hemophilia.Recommendations from the European Working Group for Value Assessment and Funding Processes in Rare Diseases (ORPH-VAL).Tertiary prophylaxis in adults: is there a rationale?Emerging drugs for the treatment of hemophilia A and B.Improving haemophilia patient care through sharing best practice.Haemophilia care in Europe - a survey of 35 countries.Assessing options for treating haemophilia with inhibitors.Treatment for life for severe haemophilia A- A cost-utility model for prophylaxis vs. on-demand treatment.Pfizer-sponsored satellite symposium at the European Haemophilia Consortium (EHC) congress. Understanding health outcomes: focus on haemophilia.

P2860

Q26865814-D96A5396-DE0E-4326-A93A-A386B9AE73EA Q34011908-CF07EEA3-F2E1-4FAC-8641-0057A0C5CD93 Q35610429-4E251B56-9D37-45E7-99B2-302ECB66BA31 Q35821757-6C0B7845-E10F-46B9-802E-E7B1A1F88A87 Q37692633-CA774B24-32B2-43F7-8FEC-BE9DA634CBE9 Q38013763-D8F2C07C-96F1-4824-BDEC-901E340254A0 Q38933707-01E6E2F9-569D-4DBF-BC47-39C2092E3CC4 Q42643647-3F4D5A67-F8A1-4816-8025-FBAE85F64BC0 Q44041201-57AB971D-C843-447F-A639-B5E887801A5B Q45874793-D4224F83-D439-4640-BCE2-9F4DEB870C74 Q45886106-49E09F66-DEFB-4013-8E0A-BEE963C30B55 Q45886531-CAE03796-9407-47A3-B309-B7551A7427EF

P2860

Health technology assessment and haemophilia.

http://www.wikidata.org/entity/Q37984093

description

article científic

@ca

article scientifique

@fr

articol științific

@ro

articolo scientifico

@it

artigo científico

@gl

artigo científico

@pt

artigo científico

@pt-br

artikel ilmiah

@id

artikull shkencor

@sq

artículo científico

@es

name

Health technology assessment and haemophilia.

@en

Health technology assessment and haemophilia.

@nl

type

label

Health technology assessment and haemophilia.

@en

Health technology assessment and haemophilia.

@nl

prefLabel

Health technology assessment and haemophilia.

@en

Health technology assessment and haemophilia.

@nl

P1433

Q37984093-BCCFD53C-DFE0-4E38-8DC7-6EF83D83F1EB

P1476

Q37984093-077B20B5-1143-40B0-97C9-5DE3EAD54CB7

P2093

Q37984093-9CE2C71C-D3B6-4226-8067-B10B850446EA

Q37984093-DBCAA2F4-B167-465D-90A2-5B55B755FCCF

P2860

Q37984093-039FB696-9189-4F75-A997-54FA6F72C248

Q37984093-1E41F80C-5B5C-4678-A816-479DE5EF7920

Q37984093-2CB7376A-8CDF-4479-A5B3-81D2B2B10C39

Q37984093-2D4E1C54-17D8-441F-828E-6CAF93D2B3AF

Q37984093-4757F40B-2059-4698-A43E-210CFFA102FF

Q37984093-4836A7A0-E67D-4EAC-8F69-49FC6DDC221F

Q37984093-5F19B197-46F8-447E-AE2C-0D7CA30D2945

Q37984093-619F21EE-5E00-4B29-BE15-062B50C419FE

Q37984093-6C4FC14E-1477-4A87-97C4-7806815F50F2

Q37984093-77103C83-FA80-48DF-9D7A-3CE4C7294E0D

P304

Q37984093-F59D5788-6FA7-498A-8EE0-C0D8D0122B8B

P31

Q37984093-E3FF0A3D-7B02-44F0-9159-D91F2D9F85B3

P356

Q37984093-2260222F-DAEA-46AF-B0C4-D90D232E9927

P433

Q37984093-30B89B60-465C-4726-A024-985CDCBCC4DD

P478

Q37984093-AD88267D-79BD-436B-B65A-77D2BB3859E3

P50

Q37984093-99A974F4-C2A8-4A28-B2A4-380EAAE9F649

P577

Q37984093-AAB4CF3F-EA21-4D21-A4D2-11E21403C84D

P698

Q37984093-EE81BBBE-0B53-4184-9BAE-76D0751E8EA0

P921

Q37984093-8D99F481-3386-493D-B69E-2554E1CDF480

P356

J.1365-2516.2012.02754.X

P1433

P1476

Health technology assessment and haemophilia.

@en

P2093

B O'Mahony

http://www.w3.org/2001/XMLSchema#string

J Cassar

http://www.w3.org/2001/XMLSchema#string

P2860

Misimagining the unimaginable: The disability paradox and health care decision making

Preference-based measures in economic evaluation in health care.

Treatment of haemophilia A and B and von Willebrand's disease: summary and conclusions of a systematic review as part of a Swedish health-technology assessment.

Pharmaco-economics of blood transfusion safety: review of the available evidence.

What is the price of life and why doesn't it increase at the rate of inflation?

Cost-utility analysis of prophylaxis versus treatment on demand in severe hemophilia A

A Bayesian approach to the assessment of inhibitor risk in studies of factor VIII concentrates.

Cost-utility analysis of Canadian tailored prophylaxis, primary prophylaxis and on-demand therapy in young children with severe haemophilia A.

Emerging clinical concerns in the ageing haemophilia patient.

Revisiting the cost-effectiveness of primary prophylaxis with clotting factor for the treatment of severe haemophilia A.

P304

152-157

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1111/J.1365-2516.2012.02754.X

http://www.w3.org/2001/XMLSchema#string

P433

2

http://www.w3.org/2001/XMLSchema#string

P478

18

http://www.w3.org/2001/XMLSchema#string

P50

Albert Farrugia

P577

2012-03-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

22335450

http://www.w3.org/2001/XMLSchema#string

P921